Evidence Hub

The predictive value of circulating inflammatory and immune biomarkers for stroke-associated pneumonia following endovascular therapy in patients with acute anterior circulation large vessel occlusion infarction: a prospective cohort study

Yong-chao Lin, Ting Lin, Biyu Wu, Zhu-Quan Hong, Zhihua Zhu, Xiaorong Zhang, Quanlong Hong, Pingzhen Lin

Frontiers in Neurology, 2026

2 citations

Abstract

Objective To investigate the changes in circulating biomarkers of patients with acute anterior circulation large vessel occlusive cerebral infarction (ACLVO) following endovascular therapy (EVT), and to explore their potential utility as early predictors for the development of stroke-associated pneumonia (SAP). Methods Peripheral blood samples were collected from ACLVO patients on days 1, 3, and 7 following EVT. Samples were analyzed to detect monocyte human leukocyte antigen-DR (mHLA-DR) expression level, along with plasma levels of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT). Results Multivariate binary logistic regression analysis adjusted for clinical confounders identified decreased mHLA DR expression at day 1 and dysphagia as independent SAP predictors (P < 0.001). Compared to the non-SAP group, the SAP group showed significantly lower expression of mHLA-DR on days 1, 3, and 7 (P < 0.001), plasma IL-6 and CRP levels were significantly higher on days 3 and 7 (P < 0.05), as was the plasma PCT level on day 7 (P < 0.05). Infarct volume was significantly larger in the SAP group (P < 0.001). In predictive modeling, expression of mHLA-DR on days 1 alone yielded an AUC of 0.914 (optimal cutoff: 55.75%). Decision curve analysis showed that expression of mHLA-DR on days 1 offered greater net benefit than other clinical scores, and that combining it with the A2DS2 score provided a superior, stable net benefit for SAP prediction. Conclusion In this…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free